KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Inventory (2017 - 2025)

BeOne Medicines (ONC) has disclosed Inventory for 9 consecutive years, with $608.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 22.88% to $608.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $608.2 million, a 22.88% increase, with the full-year FY2025 number at $608.2 million, up 22.88% from a year prior.
  • Inventory was $608.2 million for Q4 2025 at BeOne Medicines, up from $531.7 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $608.2 million in Q4 2025 to a low of $73.0 million in Q1 2021.
  • A 5-year average of $348.6 million and a median of $319.1 million in 2023 define the central range for Inventory.
  • Peak YoY movement for Inventory: skyrocketed 324.99% in 2021, then rose 8.94% in 2023.
  • BeOne Medicines' Inventory stood at $242.6 million in 2021, then rose by 16.37% to $282.3 million in 2022, then skyrocketed by 47.38% to $416.1 million in 2023, then rose by 18.95% to $495.0 million in 2024, then rose by 22.88% to $608.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Inventory are $608.2 million (Q4 2025), $531.7 million (Q3 2025), and $502.9 million (Q2 2025).